Skip to main content

NCT00216593 - Treatment of Severe Alzheimer's Disease in a Residential Home, Nursing Home, or Geriatric Residential Setting: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Randomised, Doubleblind, Placebo-Controlled Study

Treatment of Severe Alzheimer's Disease in a Residential Home, Nursing Home, or Geriatric Residential Setting: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Randomised, Doubleblind, Placebo-Controlled Study


Data Specification

Not Yet Available


Annotated CRF

Not Yet Available

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.

Product Info

Generic Name
Galantamine
Product Name
RAZADYNEĀ®
Therapeutic Area
Behaviors and Mental Disorders
Enrollment
415
Product Class
Alzheimer's Disease - Cholinesterase Inhibitors
Sponsor Protocol Number
GAL-ALZ-302 (PMID # 19042161-CR003940)
Data Holder
Johnson & Johnson
Condition Studied
Alzheimer Disease

Supporting Documentation

Annotated Case Report Form (CRF)
Clinical Study Report
Collected Datasets
Data Definition Specification
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
3

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.